Evidence map›Paper›PMID 32231590›Full record

ReviewFrontiers in physiology2020

Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence.

Bianca Domingues Massolini, Stephanie San Gregorio Contieri, Giulia Severini Lazarini, Paula Antoun Bellacosa, Mirela Dobre, Georg Petroianu, Andrei Brateanu, Luciana Aparecida Campos, Ovidiu Constantin Baltatu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Bianca Domingues MassoliniCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Stephanie San Gregorio ContieriCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Giulia Severini LazariniCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Paula Antoun BellacosaCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Mirela DobreDivision of Nephrology and Hypertension, University Hospitals, Cleveland, OH, United States.
Georg PetroianuCollege of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.
Andrei BrateanuMedicine Institute, Cleveland Clinic, Cleveland, OH, United States.
Luciana Aparecida CamposCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Ovidiu Constantin BaltatuCenter of Innovation, Technology and Education-CITÉ, São José dos Campos Technology Park, São José dos Campos, São Paulo, Brazil.
Anhembi Morumbi University · BRCleveland Clinic · USKhalifa University of Science and Technology · AEUniversity Hospitals of Cleveland · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this systematic review was to investigate the scientific evidence to support the use of direct renin inhibitors (DRIs) in diabetic nephropathy (DN). MEDLINE was searched for articles reported until 2018. A standardized dataset was extracted from articles describing the effects of DRIs on plasma renin activity (PRA) in DN. A total of three clinical articles studying PRA as an outcome measure for DRIs use in DN were identified. These clinical studies were randomized controlled trials (RCTs): one double-blind crossover, one

Indexed as

diabetes mellitusdiabetic nephropathyplasma renin activityrenin- angiotensin systemrenin inhibitor

Identifiers

PMID32231590
PMCPMC7082742
OpenAlexW3010850414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.